Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population
Author | Nasrallah, Gheyath K |
Author | Dargham, Soha R |
Author | Shurrab, Farah |
Author | Al-Sadeq, Duaa W |
Author | Al-Jighefee, Hadeel |
Author | Chemaitelly, Hiam |
Author | Al Kanaani, Zaina |
Author | Al Khal, Abdullatif |
Author | Al Kuwari, Einas |
Author | Coyle, Peter |
Author | Jeremijenko, Andrew |
Author | Kaleeckal, Anvar Hassan |
Author | Latif, Ali Nizar |
Author | Shaik, Riyazuddin Mohammad |
Author | Rahim, Hanan F Abdul |
Author | Yassine, Hadi M |
Author | Al Kuwari, Mohamed G |
Author | Qotba, Hamda |
Author | Al Romaihi, Hamad Eid |
Author | Tang, Patrick |
Author | Bertollini, Roberto |
Author | Al-Thani, Mohamed H |
Author | Althani, Asmaa A |
Author | Abu-Raddad, Laith J |
Available date | 2021-06-08T09:19:34Z |
Publication Date | 2021-06-01 |
Publication Name | scientific reports |
Identifier | http://dx.doi.org/10.1038/s41598-021-91235-x |
Citation | Nasrallah, G.K., Dargham, S.R., Shurrab, F. et al. Analytic comparison between three high-throughput commercial SARS-CoV-2 antibody assays reveals minor discrepancies in a high-incidence population. Sci Rep 11, 11837 (2021). https://doi.org/10.1038/s41598-021-91235-x |
ISSN | 2045-2322 |
Abstract | Performance of three automated commercial serological IgG-based assays was investigated for assessing SARS-CoV-2 "ever" (past or current) infection in a population-based sample in a high exposure setting. PCR and serological testing was performed on 394 individuals. SARS-CoV-2-IgG seroprevalence was 42.9% (95% CI 38.1-47.8%), 40.6% (95% CI 35.9-45.5%), and 42.4% (95% CI 37.6-47.3%) using the CL-900i, VidasIII, and Elecsys assays, respectively. Between the three assays, overall, positive, and negative percent agreements ranged between 93.2-95.7%, 89.3-92.8%, and 93.8-97.8%, respectively; Cohen's kappa statistic ranged from 0.86 to 0.91; and 35 specimens (8.9%) showed discordant results. Among all individuals, 12.5% (95% CI 9.6-16.1%) had current infection, as assessed by PCR. Of these, only 34.7% (95% CI 22.9-48.7%) were seropositive by at least one assay. A total of 216 individuals (54.8%; 95% CI 49.9-59.7%) had evidence of ever infection using antibody testing and/or PCR during or prior to this study. Of these, only 78.2%, 74.1%, and 77.3% were seropositive in the CL-900i, VidasIII, and Elecsys assays, respectively. All three assays had comparable performance and excellent agreement, but missed at least 20% of individuals with past or current infection. Commercial antibody assays can substantially underestimate ever infection, more so when infection rates are high. |
Language | en |
Publisher | Nature Research |
Subject | SARS‑CoV‑2 antibody assays |
Type | Article |
Files in this item
This item appears in the following Collection(s)
-
Biomedical Research Center Research [709 items ]
-
Biomedical Sciences [692 items ]
-
COVID-19 Research [799 items ]